Sharma D, Verma S, Vaidya S, Kalia K, Tiwari V (2018) Recent updates on GLP-1 agonists: current advancements & challenges
UTX negatively regulates the expression of ATF4 and its downstream target genes, such as ChaC1, by maintaining histone marks that prevent their activation
When to seek medical advice: Persistent or severe nausea and vomiting that prevents adequate fluid or food intake Signs of dehydration (dark urine, dizziness, extreme thirst) Severe abdominal pain, which could indicate pancreatitis (a rare but serious side effect) Symptoms of hypoglycaemia (shakiness, sweating, confusion, rapid heartbeat) Sudden visual changes (retinopathy risk, particularly with rapid HbA1c improvement) Symptoms of gallbladder disease (severe upper abdominal pain, jaundice) Signs of severe allergic reaction (swelling of face/lips/tongue, breathing difficulty) call 999/112 Your healthcare team will typically review your HbA1c about 3 months after starting treatment and after each dose change
Timeline and Availability Retatrutide is currently in Phase 3 trials (as of 2025)
